Bora Biologics to Manufacture NYPOZI(TM) at San Diego Facility in Partnership with InvaGen Pharmaceuticals, a Cipla Group Company
-
From rubble to music: Gaza's Oud repairman
-
Ntamack aims to bring Toulouse Top 14 win 'energy' to Nations Championship campaign
-
Cycling industry bets on smart bikes to boost sales
-
'High-strung' camels race in Australian outback
-
In Idaho, the next generation of US nuclear reactors nears reality
-
Algeria and Austria reach World Cup knockouts after 3-3 thriller
-
Africa the winner of expanded World Cup amid mixed fortunes for minnows
-
DR Congo advance but Iran out as wild World Cup group stage wraps
-
Asia's vendors grapple with rising costs of ever-present plastics
-
Austria and Algeria reach World Cup knockouts after 3-3 thriller
-
Messi scores again as Argentina head into World Cup last 32 on a high
-
Where are they? Dogs disappear before South Korea meat ban
-
Wissa proud to deliver World Cup joy to war-torn DR Congo
-
China's bull wrestlers fight to keep tradition alive
-
South Korea's 'dismal' World Cup ends in group phase
-
England top group to set up DR Congo World Cup clash, Portugal held
-
Colombia and Portugal through to World Cup last 32 after thrilling draw
-
England moving on at World Cup but questions linger
-
Wissa sends DR Congo into World Cup last 32 clash with England
-
Venezuela quakes kill 1,400 as time running out to find survivors
-
A painful wait by a pile of rubble in quake-hit Venezuela
-
Australia World Cup goalkeeper Patrick Beach has beach named after him
-
Tuchel delighted to have Bellingham in 'sweet spot' for England at World Cup
-
Take brutally hot weather seriously, heatstroke survivor warns
-
Bellingham says 'job done' but England must improve at World Cup
-
Australia boosts shark-spotting drone coverage at Sydney beaches
-
Scotland boss Clarke resigns after World Cup exit confirmed: official
-
Kane, Bellingham on target as England clinch top spot
-
Croatia battle past Ghana to sew up World Cup Last 32 spot
-
Bellingham, Kane score as England beat Panama to reach World Cup last 32
-
Canada's Davies 'available' for historic knockout clash
-
Ryu takes one-shot lead over Henderson at Women's PGA Championship
-
Hovland seizes one-shot PGA Travelers lead over Scheffler
-
Jangoo and Chase put West Indies in control against Sri Lanka
-
Mauvaka double inspires Toulouse to fourth-straight Top 14 in storm-impacted final
-
World Cup star Gakpo requests privacy after death of unborn son
-
Solidarity, sadness among Venezuelans made destitute by quake
-
Aid planes landing at partially reopened Venezuela airport after quakes
-
Spain's Williams hits out at Uruguay over World Cup injury
-
'We need help': Venezuelans furious at slow official response to quakes
-
World's largest particle smasher halts for upgrade to boost hunt for dark matter
-
Venus Williams relishes 'very special' Wimbledon reunion with sister Serena
-
Ex-Olympic medallist Canderloro elected French Ice Sports chief
-
Ravindra leads New Zealand rally in England finale after Archer's double strike
-
Prince Harry and family to stay at royal residences on UK visit
-
Wimbledon 'towel thief' Swiatek back on the trophy hunt
-
'Why not?': Cape Verde eye seismic World Cup shock against Argentina
-
Venezuela earthquake deaths near 1,000, with millions more in need
-
Russell snatches controversial pole in Austria after Verstappen crash
-
French Open champs head to Wimbledon wrestling with new-found status
Bora Biologics to Manufacture NYPOZI(TM) at San Diego Facility in Partnership with InvaGen Pharmaceuticals, a Cipla Group Company
SAN DIEGO, CA / ACCESS Newswire / September 25, 2025 / Bora Biologics, a leading contract development and manufacturing organization (CDMO) specializing in biologics, proudly announces its partnership with InvaGen Pharmaceuticals Inc., a wholly owned subsidiary of Cipla Limited, for the manufacture of NYPOZI™ (biosimilar to Neupogen®) at its FDA-registered facility in San Diego, California.
This collaboration signifies a major advancement in the biopharmaceutical sector, as NYPOZI™ is set to become the first FDA-approved biosimilar developed by a Taiwanese biopharma company to launch in the U.S. market. Bora Biologics will leverage its U.S. commercial manufacturing capabilities to support the production of this innovative therapy.
Bora Biologics' San Diego facility is equipped with advanced technology and rigorous GMP processes, enabling the efficient manufacture of high-quality biologics. This partnership underscores Bora Biologics' commitment to meeting the growing demands of the biopharmaceutical industry while ensuring the highest standards of quality and compliance.
"We are thrilled to be InvaGen's manufacturing partner for NYPOZI™ in the United States," said Stephen Lam, CEO of Bora Biologics. "Our FDA-registered facility is designed to meet the stringent requirements of biologics manufacturing, and we are dedicated to supporting this product's journey to market making more affordable medicine available to patients."
Marc Falkin, CEO, Cipla North America commented, "Our foray into the U.S. biosimilars signals a key milestone for Cipla. We are pleased to work with Bora Biologics to manufacture NYPOZI™ (biosimilar to Neupogen®) and improve access to high-quality affordable treatment. This further aligns with our purpose of 'Caring for Life' by making advanced therapies available to those in need, ultimately enhancing patient outcomes in the US."
This collaboration represents a significant milestone in Bora Biologics' mission to provide comprehensive manufacturing solutions and contribute to the advancement of life-saving therapies within its expanding GMP facility with two new 2000L bioreactors for biologics manufacturing opening in Q1 2026.
About Bora Biologics
Bora Biologics is a global CDMO offering agile, comprehensive end-to-end solutions for biopharma companies worldwide. With a proven track record of over 100 successful cGMP manufacturing batches, Bora Biologics leverages its state-of-the-art, FDA-registered facility in the U.S. and deep expertise in biologics development and manufacturing-including its own FDA-licensed and Health Canada approved product-to enhance time and cost efficiencies while ensuring effective pathways to market for its clients. Bora Biologics combines innovative early-phase development and late-stage manufacturing capabilities with the expertise and reputation of Bora Pharmaceuticals for flexible and scalable fill/finish services, including stability testing and final packaging of clinical and commercial products. Bora Biologics is a dba of Tanvex BioPharma USA, Inc.
Website
https://borabiologics.com
Media Contact
[email protected]
CDMO Inquiries
[email protected]
SOURCE: Bora Biologics
View the original press release on ACCESS Newswire
A.Malone--AMWN
